https://orcid.org/0000-0001-8450-4916
References
- Rabe KF, Martinez FJ, Ferguson GT, et al. A Phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. Respir Med. 2019; 158:59–66. doi:10.1016/j.rmed.2019.08.010.
- Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. 2doi:10.1056/NEJMoa1916046.
- Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. The Lancet. 2016;388(10048):963–973. Sep 3. doi:10.1016/S0140-6736(16)31354-X.
- Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. The Lancet. 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-5.
- Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901.
- Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi: 10.1164/rccm.201703-0449OC.
- Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. The Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X.
- Brusselle G, Pavord ID, Landis S, et al. Blood eosinophil levels as a biomarker in COPD. Respir Med. 2018;138:21–31. doi:10.1016/j.rmed.2018.03.016.
- Blazer A. (@ablazermd) “Would we expect to see a significant difference between eos levels of 150? Eos > 300 is generally felt to be the relevant cut off for favouring the use of ICS. (However this was a small proportion of pts in this study).” August 27, 2020. 8:02pm Tweet
- Stanbrook M. (@drstanbrook). “We actually know from other studies that the effect is continuous, not dichotomous. Higher eos = greater ICS response. Supplement has a figure showing exactly that. “August 27, 2020. 8:57pm Tweet.
- Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. The Lancet Respiratory Medicine. 2017; 5(12):956–967. doi:10.1016/S2213-2600(17)30432-0.
- Blazer A. (@ablazermd) “Part of what is novel in this study is the two different ICS doses - why not compare between them? They actually state "the trial was not powered to detect a significant difference between the triple-therapy regimens." Why not? It was to compare between the other grps. (1/2)” August 27, 2020. 8:19pm Tweet
- Vestbo J, Anderson JA, Brook RD, Calverley PM, Summit Investigators, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. The Lancet. 2016;387(10030):1817–1826.,. Apr 30 doi:10.1016/S0140-6736(16)30069-1.